The summaries are free for public
use. The Chronic Liver Disease
Foundation will continue to add and
archive summaries of articles deemed
relevant to CLDF by the Board of
Trustees and its Advisors.
Abstract Details
A three-pronged epigenetic approach to the treatment of hepatocellular carcinoma
Hlady RA1, Robertson KD1. Hepatology. 2018 Aug 2. doi: 10.1002/hep.30133. [Epub ahead of print]
Author information
1
Department of Molecular Pharmacology and Experimental Therapeutics, Center for Individualized Medicine Epigenomics Program, Mayo Clinic, Rochester, MN, 55905.
Abstract
Hepatocellular carcinoma (HCC) is among the fastest growing causes of cancer related death in the United States due to a lack of early detection strategies, increased incidence driven in part by metabolic syndrome, and limited treatment options. Multikinase inhibitors (sorafenib/regorafenib) and immune checkpoint inhibitors (nivolumab) are the three FDA-approved drugs for HCC treatment, with only the latter having potential to dramatically improve outcome, emphasizing the unmet need for alternative therapeutic strategies. In this issue of HEPATOLOGY, Liu et al. explore the role of the DNA methyltransferase inhibitor (DNMTi), SGI-110, for the treatment of HCC in preclinical models (1). SGI-110 (guadecitibine) is a second-generation DNMTi in which 5-aza-2'-deoxycytidine (5-azadC or decitabine) is linked to deoxyguanosine, conferring additional stability and longer half-life due to protection from deamination.